CRANBURY, N.J., May 25, 2012
CRANBURY, N.J., May 25, 2012 /PRNewswire/ -- Oncobiologics, Inc. announced today that it has filled two important leadership positions with established biopharmaceutical industry experts. Stephen J. McAndrew, Ph.D. is now Vice President, Business Development and Vincent J. Benn, Ph.D. has joined the company as Vice President, Clinical & Regulatory Affairs. The company also announced its new Scientific Advisory Board, which will be headed by Joseph Bertino, M.D., currently Chief Scientific Officer and Associate Director of the Cancer Institute of New Jersey at UMDNJ-Robert Wood Johnson Medical School.
"Oncobiologics is fortunate to add pros like Steve and Vince to our management team. Their interest in Oncobiologics is an indication that our existing team and recent technical progress continue to attract the best and the brightest from the industry," said Oncobiologics Founder & CEO Pankaj Mohan, Ph.D.
Mohan continued, "In addition, the establishment of our Scientific Advisory Board with Dr. Bertino at the helm is a watershed moment for Oncobiologics. This external group of experts will provide critical clinical and strategic direction to guide the progress of our novel biotherapeutics."
Dr. McAndrew is responsible for the company's revenue growth strategy and initiatives, establishing and managing all collaborative research and commercial product partnerships, and sourcing selected investment opportunities. Prior to joining Oncobiologics, Dr. McAndrew served as Vice President, Business Development for Xenogen Biosciences, Caliper Life Sciences and Taconic Biosciences. Previously, he served as Vice President, Pharmaceutical Business Development for Lexicon Pharmaceuticals and Director, Biotechnology Licensing for Bristol-Myers Squibb Company. Earlier, Dr. McAndrew led applied research programs within Discovery-Oncology at Bristol-Myers Squibb, and exploratory research in the Roche Institute of Molecular Biology at Hoffmann La-Roche.
Dr. Benn is responsible for Oncobiologics' clinical programs, regulatory strategies and regulatory affairs. He brings more than 30 years of clinical and regulatory drug and biologics development experience to Oncobiologics. Previously, he was Vice President Clinical & Regulatory Affairs at Essential Pharmaceuticals, Vice President Worldwide Clinical Operations at Discovery Labs, and Global Clinical Program Director at Aventis Behring LLC. He brings extensive experience in the development and defense of clinical development plans before FDA, EMEA, MCA, MPA, and the Paul Erlich Institute (PEI).
In addition to Dr. Bertino, Scientific Advisory Board members include Debabrata Banerjee, Ph.D., Associate Professor of Medicine & Pharmacology at Robert Wood Johnson Medical School & Adjunct Associate Prof at New York Medical College; Igor A. Astsaturov, M.D., Ph.D., Assistant Professor and Attending Oncologist at Fox Chase Cancer Center in Philadelphia; Hossein Borghaei, D.O., M.S., Director of Thoracic Medical Oncology and Co-Leader, Thoracic Cancer Service at Fox Chase Cancer Center; Matt Robinson, Ph.D., Assistant Professor in the Developmental Therapeutics Program at Fox Chase Cancer Center; Mak Jawadekar, Ph.D., formerly Director, Portfolio Management & Analytics, Pfizer, Inc. and Vice President of Asia CRG at Pfizer Inc.; and Mauricio Futran, Ph.D., Professor and Chair of Chemical and Biochemical Engineering at Rutgers University, with nearly 30 years of experience at Merck & Co. and Bristol-Myers Squibb.
About Oncobiologics, Inc.
Headquartered in Cranbury, N.J., Oncobiologics is a biopharmaceutical company developing a pipeline of next-generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. The company's proprietary TRIDENT™ platform leverages fully human single-chain, bi-specific antibodies with HSA binding designed for overall significantly enhanced efficacy, safety, and pharmacokinetics with targeted delivery. For more information, please visit www.oncobiologics.com or call 609-619-3990.
Rick GregoryR.C. Gregory & Co.email@example.com
This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.
SOURCE Oncobiologics, Inc.PR Newswire
Last updated on: 25/05/2012